Daniel W Cramer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6235420/publications.pdf

Version: 2024-02-01

121 papers	8,537 citations	66250 44 h-index	54771 88 g-index
121 all docs	121 docs citations	121 times ranked	12279 citing authors

#	Article	IF	Citations
1	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871.	1.4	8
2	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	1.1	2
3	Application of a novel microscopic technique for quantifying CA125 binding to circulating mononuclear cells in longitudinal specimens during treatment for ovarian cancer. Journal of Ovarian Research, 2022, 15, 28.	1.3	1
4	Ovarian Cancer Ascites Inhibits Transcriptional Activation of NK Cells Partly through CA125. Journal of Immunology, 2022, 208, 2227-2238.	0.4	6
5	A Translational Model to Improve Early Detection of Epithelial Ovarian Cancers. Frontiers in Oncology, 2022, 12, 786154.	1.3	1
6	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal of the National Cancer Institute, 2021, 113, 301-308.	3.0	8
7	Differential blood count as triage tool in evaluation of pelvic masses. International Journal of Gynecological Cancer, 2021, 31, 733-743.	1.2	4
8	Racial/ethnic differences in average CA125 and CA15.3 values and its correlates among postmenopausal women in the USA. Cancer Causes and Control, 2021, 32, 299-309.	0.8	4
9	Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 927-935.	1.1	10
10	Self-reported infertility diagnoses and treatment history approximately 20 years after fertility treatment initiation. Fertility Research and Practice, 2021, 7, 7.	4.1	7
11	Epidemiologic and biologic correlates of serum HE4 and CA125 in women from the National Health and Nutritional Survey (NHANES). Gynecologic Oncology, 2021, 161, 282-290.	0.6	3
12	Characterization of Cell-Bound CA125 on Immune Cell Subtypes of Ovarian Cancer Patients Using a Novel Imaging Platform. Cancers, 2021, 13, 2072.	1.7	6
13	Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association. Gynecologic Oncology, 2021, , .	0.6	5
14	The association of talc use and ovarian cancer: biased or causal. Gynecologic Oncology Reports, 2021, 41, 100896.	0.3	0
15	Plasmonic Nanoparticle-Based Digital Cytometry to Quantify MUC16 Binding on the Surface of Leukocytes in Ovarian Cancer. ACS Sensors, 2020, 5, 2772-2782.	4.0	10
16	Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer. Epidemiology, 2020, 31, 402-408.	1.2	12
17	Genital Powder Use and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2020, 323, 2095.	3.8	1
18	Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncology, 2020, 6, e200421.	3.4	78

#	Article	IF	Citations
19	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	0.6	15
20	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.4	49
21	Statin therapy and association with ovarian cancer risk in the New England Case Control (NEC) study. International Journal of Cancer, 2019, 144, 991-1000.	2.3	37
22	Migration of Talc From the Perineum to Multiple Pelvic Organ Sites. American Journal of Clinical Pathology, 2019, 152, 590-607.	0.4	10
23	Douching, Talc Use, and Risk for Ovarian Cancer and Conditions Related to Genital Tract Inflammation. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1835-1844.	1.1	9
24	Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2019, 48, 822-830.	0.9	22
25	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	1.3	6
26	Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2019, 30, 537-547.	0.8	16
27	Correlative polarizing light and scanning electron microscopy for the assessment of talc in pelvic region lymph nodes. Ultrastructural Pathology, 2019, 43, 13-27.	0.4	8
28	Predicting Circulating CA125 Levels among Healthy Premenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1076-1085.	1.1	9
29	A comprehensive geneâ€“environment interaction analysis in Ovarian Cancer using genomeâ€wide significant common variants. International Journal of Cancer, 2019, 144, 2192-2205.	2.3	12
30	Perspectives on Ovarian Cancer From SEER: Today and Tomorrow. Journal of the National Cancer Institute, 2019, 111, 5-6.	3.0	7
31	Tumorâ€associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. International Journal of Cancer, 2018, 143, 515-526.	2.3	18
32	Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 790-804.	1.1	6
33	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	2.9	15
34	Ovarian cancer risk, <scp>ALDH</scp>2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium. Cancer Science, 2018, 109, 435-445.	1.7	10
35	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. American Journal of Epidemiology, 2018, 187, 366-377.	1.6	8
36	Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 174-182.	1.1	20

#	Article	IF	Citations
37	Ovarian cancer early detection by circulating <scp>CA</scp>125 in the context of antiâ€<scp>CA</scp>125 autoantibody levels: Results from the <scp>EPIC</scp> cohort. International Journal of Cancer, 2018, 142, 1355-1360.	2.3	24
38	Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1483-1490.	1.1	29
39	Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. Journal of Pathology, 2018, 246, 459-469.	2.1	23
40	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
41	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
42	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	2.9	23
43	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal of Cancer, 2017, 140, 2422-2435.	2.3	25
44	Autoantibody biomarkers for the detection of serous ovarian cancer. Gynecologic Oncology, 2017, 146, 129-136.	0.6	53
45	Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort. Journal of Ovarian Research, 2017, 10, 20.	1.3	22
46	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
47	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal of Cancer, 2017, 116, 1223-1228.	2.9	13
48	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes and Control, 2017, 28, 469-486.	0.8	28
49	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. British Journal of Cancer, 2017, 117, 1063-1069.	2.9	16
50	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1470-1473.	1.1	10
51	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	1.1	3
52	Diagnostic potential for a serum miRNA neural network for detection of ovarian cancer. ELife, 2017, 6, .	2.8	106
53	Signatures of reproductive events on blood counts and biomarkers of inflammation: Implications for chronic disease risk. PLoS ONE, 2017, 12, e0172530.	1.1	12
54	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	0.9	71

#	Article	IF	Citations
55	The Association Between Talc Use and Ovarian Cancer. Epidemiology, 2016, 27, 334-346.	1.2	63
56	A prognostically relevant miRNA signature for epithelial ovarian cancer. Lancet Oncology, The, 2016, 17, 1032-1033.	5.1	11
57	Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers. Proteomics - Clinical Applications, 2016, 10, 720-731.	0.8	26
58	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstetrics and Gynecology, 2016, 127, 828-836.	1.2	39
59	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Human Molecular Genetics, 2016, 25, 3600-3612.	1.4	17
60	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
61	A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. Clinical Cancer Research, 2016, 22, 4664-4675.	3.2	80
62	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	1.8	19
63	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	0.9	111
64	A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. International Journal of Cancer, 2016, 139, 2646-2654.	2.3	7
65	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
66	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology, 2016, 41, 71-79.	0.8	20
67	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 446-454.	1.1	9
68	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
69	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	0.8	13
70	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	1.1	44
71	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
72	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	1.1	28

#	Article	IF	Citations
73	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	0.6	15
74	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	5.8	63
75	Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	1.3	24
76	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	1.4	68
77	Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in Relation to Ovarian Cancer Risk and Survival. PLoS ONE, 2014, 9, e88334.	1.1	22
78	Evidence of Differential Effects of Vitamin D Receptor Variants on Epithelial Ovarian Cancer Risk by Predicted Vitamin D Status. Frontiers in Oncology, 2014, 4, 286.	1.3	9
79	Variation in NF-ÎºB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	1.1	13
80	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 2014, 106, djt431-djt431.	3.0	186
81	Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecologic Oncology, 2014, 132, 542-550.	0.6	128
82	Prior appendectomy does not protect against subsequent development of malignant or borderline mucinous ovarian neoplasms. Gynecologic Oncology, 2014, 132, 328-333.	0.6	17
83	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
84	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
85	Puerperal mastitis: a reproductive event of importance affecting anti-mucin antibody levels and ovarian cancer risk. Cancer Causes and Control, 2013, 24, 1911-1923.	0.8	10
86	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 caseâ€“control studies. Cancer Causes and Control, 2013, 24, 989-1004.	0.8	84
87	Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Caseâ€“Control Study. International Journal of Cancer, 2013, 133, 2415-2421.	2.3	53
88	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	1.6	169
89	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	5.8	144
90	Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. International Journal of Epidemiology, 2013, 42, 579-589.	0.9	146

#	Article	IF	Citations
91	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	5.8	98
92	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of caseâ€“control studies. Lancet Oncology, The, 2012, 13, 385-394.	5.1	753
93	The Epidemiology of Endometrial and Ovarian Cancer. Hematology/Oncology Clinics of North America, 2012, 26, 1-12.	0.9	158
94	Assessing Ovarian Cancer Risk When Considering Elective Oophorectomy at the Time of Hysterectomy. Obstetrics and Gynecology, 2011, 117, 1042-1050.	1.2	62
95	Epidemiologic perspective on immune-surveillance in cancer. Current Opinion in Immunology, 2011, 23, 265-271.	2.4	68
96	Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens. Cancer Prevention Research, 2011, 4, 365-374.	0.7	256
97	Mumps and ovarian cancer: modern interpretation of an historic association. Cancer Causes and Control, 2010, 21, 1193-1201.	0.8	47
98	Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecologic Oncology, 2010, 119, 462-468.	0.6	28
99	Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature Genetics, 2010, 42, 880-884.	9.4	235
100	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	9.4	321
101	CA125 Immune Complexes in Ovarian Cancer Patients with Low CA125 Concentrations. Clinical Chemistry, 2010, 56, 1889-1892.	1.5	30
102	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	9.4	276
103	Consortium analysis of 7 candidate SNPs for ovarian cancer. International Journal of Cancer, 2008, 123, 380-388.	2.3	73
104	Presence of Talc in Pelvic Lymph Nodes of a Woman With Ovarian Cancer and Long-Term Genital Exposure to Cosmetic Talc. Obstetrics and Gynecology, 2007, 110, 498-501.	1.2	27
105	Conditions Associated with Antibodies Against the Tumor-Associated Antigen MUC1 and Their Relationship to Risk for Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1125-1131.	1.1	153
106	Androgen Receptor Cytosine, Adenine, Guanine Repeats, and Haplotypes in Relation to Ovarian Cancer Risk. Cancer Research, 2005, 65, 5974-5981.	0.4	79
107	Human progesterone receptor polymorphisms and implantation failure during in vitro fertilization. American Journal of Obstetrics and Gynecology, 2003, 189, 1085-1092.	0.7	33
108	The Epidemiology of Endometriosis. Annals of the New York Academy of Sciences, 2002, 955, 11-22.	1.8	396

#	Article	IF	Citations
109	Carotenoids, antioxidants and ovarian cancer risk in pre- and postmenopausal women. International Journal of Cancer, 2001, 94, 128-134.	2.3	108
110	Population based study of coffee, alcohol and tobacco use and risk of ovarian cancer. International Journal of Cancer, 2000, 88, 313-318.	2.3	101
111	Occult Ovarian Tumors in Women With BRCA1 or BRCA2 Mutations Undergoing Prophylactic Oophorectomy. Journal of Clinical Oncology, 2000, 18, 2728-2732.	0.8	182
112	Prospective Study of Talc Use and Ovarian Cancer. Journal of the National Cancer Institute, 2000, 92, 249-252.	3.0	106
113	Evaluation of a Population Roster as a Source of Population Controls: The Massachusetts Resident Lists. American Journal of Epidemiology, 1999, 150, 354-358.	1.6	21
114	Leptin in relation to carcinomaIn situ of the breast: A study of pre-menopausal cases and controls. , 1999, 80, 523-526.		116
115	Genital talc exposure and risk of ovarian cancer. , 1999, 81, 351-356.		88
116	Genital talc exposure and risk of ovarian cancer. , 1999, 81, 351.		1
117	Association of Medically Treated Depression and Age at Natural Menopause. American Journal of Epidemiology, 1995, 141, 1170-1176.	1.6	63
118	Epidemiologic evidence for uterine growth factors in the pathogenesis of ovarian cancer. Annals of Epidemiology, 1995, 5, 310-314.	0.9	74
119	Ovarian cancer and talc. A case-control study. Cancer, 1982, 50, 372-376.	2.0	184
120	TRENDS IN THE INCIDENCE OF ENDOMETRIOID AND CLEAR CELL CANCERS OF THE OVARY IN THE UNITED STATES. American Journal of Epidemiology, 1981, 114, 201-208.	1.6	38
121	Diet and cancer of endocrine target organs. Cancer, 1977, 40, 434-437.	2.0	21